TELOMIR PHARMACEUTICALS, INC.

All News Telomir Pharmaceuticals, Inc.

Equities

TELO

US87975F1049

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-14 pm EDT			5-day change	1st Jan Change
6.305 ^USD	-5.33%		+0.40%	0.00%

May. 13	Telomir Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 16	Telomir Pharmaceuticals, Inc. Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Telomir Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13	CI
Telomir Pharmaceuticals sees breakthrough potential in Anti-Aging Treatment with Telomir 1	May. 07	AQ
Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C.	Apr. 16	AQ
Telomir Pharmaceuticals, Inc. Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C	Apr. 16	CI
Telomir Pharmaceuticals, Inc. Announces Resignation of Christos Nicholoudis, Esq. as the General Counsel and A Member of the Board of Directors	Apr. 12	CI
Telomir Pharmaceuticals’ Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024	Apr. 02	AQ
Telomir Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines	Mar. 26	AQ
Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines	Mar. 26	CI
Telomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1 to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26th	Mar. 22	AQ
Telomir Pharmaceuticals Uses AI Testing Models to Show its Lead Product Candidate’s Potential in DNA Age Reversal Science	Mar. 14	AQ
Telomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore Conference	Mar. 07	AQ
Telomir Pharmaceuticals Presents Promising Pre-Clinical Data for Its Lead Development Product At Singapore Conference	Mar. 07	CI
Michael F. Roizen, MD to Increase Activities with Telomir Pharmaceuticals as Special Advisor on Age Reversal	Mar. 05	AQ
Telomir Pharmaceuticals Announces Closing of Initial Public Offering	Feb. 13	AQ
Telomir Pharmaceuticals, Inc.(NasdaqCM:TELO) added to NASDAQ Composite Index	Feb. 11	CI
Telomir Pharmaceuticals, Inc. has completed an IPO in the amount of $7 million.	Feb. 08	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Stock Market
Equities
TELO Stock
News Telomir Pharmaceuticals, Inc.

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW